85%Confidence
0Views
FDASource
2026-04-14Date
Summary
Teva Pharmaceuticals faces a Class II recall for Octreotide Acetate due to sterility concerns at its Greek contract manufacturer, indicating potential supply chain and quality control vulnerabilities. This may impact Teva's revenue from this product and increase regulatory scrutiny on its manufacturing partners.
Actionable: Monitor Teva's stock for potential impacts from recall costs and supply disruptions.
AI Confidence: 85%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now